NASDAQ Global Select • Healthcare • Biotechnology • US • USD
CymaBay Therapeutics, Inc. (CBAY) has a consensus analyst rating of Hold, based on 23 analysts covering the stock. Of those, 11 recommend buying, 12 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
